Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Earnings Data Deluge

by Zacks Equity Research

Earnings Data Deluge.

Mark Vickery headshot

Pre-Markets Improve on Big Earnings Morning

by Mark Vickery

One might say the relative volatility we started seeing in early October has continued into this month as well.

Zacks Equity Research

Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of +76.28% and +18.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Sundeep Ganoria headshot

Should You Buy Moderna Stock Ahead of Q3 Earnings Report?

by Sundeep Ganoria

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

Kanishka Das headshot

Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?

by Kanishka Das

Let's look at five pharma and biotech companies, PFE, AMGN, AZN, VTRS and MRNA, which are scheduled to release their third-quarter 2025 results this week.

Zacks Equity Research

Stay Ahead of the Game With Moderna (MRNA) Q3 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Moderna (MRNA) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Moderna (MRNA) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $27.08, marking a -3.77% move from the previous day.

Zacks Equity Research

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength?

by Zacks Equity Research

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline

by Zacks Equity Research

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.